RVTY Quote, Financials, Valuation and Earnings

Azenta has a net margin of 6.35% compared to Revvity's net margin of -28.21%. Revvity's return on equity of 3.68% beat Azenta's return on equity of -3.48%.

Revvity has a consensus price target of $124.12, signalling upside risk potential of 26.05%. On the other hand Azenta has an analysts' consensus of $33.75 which suggests that it could grow by 4.72%. Given that Revvity has higher upside potential than Azenta, analysts believe Revvity is more attractive than Azenta.

Revvity has a beta of 0.977, which suggesting that the stock is 2.331% less volatile than S&P 500. In comparison Azenta has a beta of 1.637, suggesting its more volatile than the S&P 500 by 63.674%.

Revvity has a quarterly dividend of $0.07 per share corresponding to a yield of 0.28%. Azenta offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Revvity pays 12.74% of its earnings as a dividend. Azenta pays out -- of its earnings as a dividend. Revvity's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Revvity quarterly revenues are $664.8M, which are larger than Azenta quarterly revenues of $143.4M. Revvity's net income of $42.2M is higher than Azenta's net income of -$40.5M. Notably, Revvity's price-to-earnings ratio is 41.90x while Azenta's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Revvity is 4.34x versus 2.44x for Azenta. Usually stocks with elevated PS ratios are considered overvalued.

Bionano Genomics has a net margin of 6.35% compared to Revvity's net margin of -48.04%. Revvity's return on equity of 3.68% beat Bionano Genomics's return on equity of -141.6%.

Revvity has a consensus price target of $124.12, signalling upside risk potential of 26.05%. On the other hand Bionano Genomics has an analysts' consensus of $7.33 which suggests that it could grow by 116.32%. Given that Bionano Genomics has higher upside potential than Revvity, analysts believe Bionano Genomics is more attractive than Revvity.

Revvity has a beta of 0.977, which suggesting that the stock is 2.331% less volatile than S&P 500. In comparison Bionano Genomics has a beta of 2.207, suggesting its more volatile than the S&P 500 by 120.694%.

Revvity has a quarterly dividend of $0.07 per share corresponding to a yield of 0.28%. Bionano Genomics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Revvity pays 12.74% of its earnings as a dividend. Bionano Genomics pays out -- of its earnings as a dividend. Revvity's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Revvity quarterly revenues are $664.8M, which are larger than Bionano Genomics quarterly revenues of $6.5M. Revvity's net income of $42.2M is higher than Bionano Genomics's net income of -$3.1M. Notably, Revvity's price-to-earnings ratio is 41.90x while Bionano Genomics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Revvity is 4.34x versus 0.17x for Bionano Genomics. Usually stocks with elevated PS ratios are considered overvalued.

Bruker has a net margin of 6.35% compared to Revvity's net margin of 2.17%. Revvity's return on equity of 3.68% beat Bruker's return on equity of 4.53%.

Revvity has a consensus price target of $124.12, signalling upside risk potential of 26.05%. On the other hand Bruker has an analysts' consensus of $53.95 which suggests that it could grow by 24.84%. Given that Revvity has higher upside potential than Bruker, analysts believe Revvity is more attractive than Bruker.

Revvity has a beta of 0.977, which suggesting that the stock is 2.331% less volatile than S&P 500. In comparison Bruker has a beta of 1.181, suggesting its more volatile than the S&P 500 by 18.13%.

Revvity has a quarterly dividend of $0.07 per share corresponding to a yield of 0.28%. Bruker offers a yield of 0.46% to investors and pays a quarterly dividend of $0.05 per share. Revvity pays 12.74% of its earnings as a dividend. Bruker pays out 26.7% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Revvity quarterly revenues are $664.8M, which are smaller than Bruker quarterly revenues of $801.4M. Revvity's net income of $42.2M is higher than Bruker's net income of $17.4M. Notably, Revvity's price-to-earnings ratio is 41.90x while Bruker's PE ratio is 84.21x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Revvity is 4.34x versus 1.92x for Bruker. Usually stocks with elevated PS ratios are considered overvalued.

Harvard Bioscience has a net margin of 6.35% compared to Revvity's net margin of -231.19%. Revvity's return on equity of 3.68% beat Harvard Bioscience's return on equity of -103.83%.

Revvity has a consensus price target of $124.12, signalling upside risk potential of 26.05%. On the other hand Harvard Bioscience has an analysts' consensus of $3.00 which suggests that it could grow by 596.7%. Given that Harvard Bioscience has higher upside potential than Revvity, analysts believe Harvard Bioscience is more attractive than Revvity.

Revvity has a beta of 0.977, which suggesting that the stock is 2.331% less volatile than S&P 500. In comparison Harvard Bioscience has a beta of 1.524, suggesting its more volatile than the S&P 500 by 52.373%.

Revvity has a quarterly dividend of $0.07 per share corresponding to a yield of 0.28%. Harvard Bioscience offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Revvity pays 12.74% of its earnings as a dividend. Harvard Bioscience pays out -- of its earnings as a dividend. Revvity's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Revvity quarterly revenues are $664.8M, which are larger than Harvard Bioscience quarterly revenues of $21.8M. Revvity's net income of $42.2M is higher than Harvard Bioscience's net income of -$50.3M. Notably, Revvity's price-to-earnings ratio is 41.90x while Harvard Bioscience's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Revvity is 4.34x versus 0.21x for Harvard Bioscience. Usually stocks with elevated PS ratios are considered overvalued.